Pharmacological characterisation of erenumab, Aimovig, at two calcitonin gene‐related peptide responsive receptors
British Journal of Pharmacology · 2024
DOI: 10.1111/bph.16218 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, 2024. Verfasst von Michael L Garelja und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand. Hauptthemen laut MEDLINE: Receptors, Calcitonin Gene-Related Peptide, Migraine Disorders. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS.
Abstract (Originalsprache)
Background and Purpose Calcitonin gene‐related peptide (CGRP) is involved in migraine pathophysiology. CGRP can signal through two receptors. The canonical CGRP receptor comprises the calcitonin receptor‐like receptor and receptor activity‐modifying protein 1 (RAMP1); the AMY 1 receptor comprises the calcitonin receptor with RAMP1. Drugs that reduce CGRP activity, such as receptor antagonists, are approved for the treatment and prevention of migraine. Despite being designed to target the canonical CGRP receptor, emerging evidence suggests that these antagonists, including erenumab (a monoclonal antibody antagonist) can also antagonise the AMY 1 receptor. However, it is difficult to estimate its selectivity because direct comparisons between receptors under matched conditions have not been made. We therefore characterised erenumab at both CGRP‐responsive receptors with multiple ligands, including αCGRP and βCGRP. Experimental Approach Erenumab antagonism was quantified through IC 50 and pK B experiments, measuring cAMP production. We used SK‐N‐MC cells which endogenously express the human CGRP receptor, and HEK293S and Cos7 cells transiently transfected to express either human CGRP or AMY 1 receptors. Key Results Erenumab antagonised both the CGRP and AMY 1 receptors with an ~20–120‐fold preference for the CGRP receptor, depending on the cells, agonist, analytical approach and/or assay format. Erenumab antagonised both forms of CGRP equally, and appeared to act as a competitive reversible antagonist at both receptors. Conclusion and Implications Despite being designed to target the CGRP receptor, erenumab can antagonise the AMY 1 receptor. Its ability to antagonise CGRP activity at both receptors may be useful in better understanding the clinical profile of erenumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand.
- Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand.
- School of Biological Sciences, University of Auckland, Auckland, New Zealand.
ORCID-Profile: Michael L Garelja, Tyla I Alexander, Amy Bennie, Mhairi Nimick, Jakeb Petersen, Christopher S Walker, Debbie L Hay
Förderung
- NINDS NIH HHS
Zitieren
APA
Garelja, M. L., Alexander, T. I., Bennie, A., Nimick, M., Petersen, J., Walker, C. S., & Hay, D. L. (2024). Pharmacological characterisation of erenumab, Aimovig, at two calcitonin gene‐related peptide responsive receptors. British Journal of Pharmacology. https://doi.org/10.1111/bph.16218
Vancouver
Garelja ML, Alexander TI, Bennie A, Nimick M, Petersen J, Walker CS, et al. Pharmacological characterisation of erenumab, Aimovig, at two calcitonin gene‐related peptide responsive receptors. British Journal of Pharmacology. 2024. doi:10.1111/bph.16218
BibTeX
@article{Garelja2024,
author = {Garelja, Michael L and Alexander, Tyla I and Bennie, Amy and Nimick, Mhairi and Petersen, Jakeb and Walker, Christopher S and Hay, Debbie L},
title = {Pharmacological characterisation of erenumab, Aimovig, at two calcitonin gene‐related peptide responsive receptors},
journal = {British Journal of Pharmacology},
year = {2024},
doi = {10.1111/bph.16218}
}
EUVIMED